Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis

Detalhes bibliográficos
Autor(a) principal: Rodrigo, Juan P.
Data de Publicação: 2023
Outros Autores: Sánchez-Canteli, Mario, Triantafyllou, Asterios, de Bree, Remco, Mäkitie, Antti A., Franchi, Alessandro, Hellquist, Henrik, Saba, Nabil F., Stenman, Göran, Takes, Robert P., Valero, Cristina, Zidar, Nina, Ferlito, Alfio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.1/19065
Resumo: Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present metaanalysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21–2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34–1.73; p < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50–2.30; p < 0.00001). This worse prognosis ofhigh NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90–8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47–1.80; p = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09–2.01; p = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08–2.72; p = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC.
id RCAP_4a30db37d20523f162f082b521574827
oai_identifier_str oai:sapientia.ualg.pt:10400.1/19065
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysisOropharyngeal squamous cell carcinomaMeta-analysisNeutrophil-to-lymphocyte ratioPrognosisNeutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present metaanalysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21–2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34–1.73; p < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50–2.30; p < 0.00001). This worse prognosis ofhigh NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90–8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47–1.80; p = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09–2.01; p = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08–2.72; p = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC.IDI/2021/000079I+D+I 2013–2016MDPISapientiaRodrigo, Juan P.Sánchez-Canteli, MarioTriantafyllou, Asteriosde Bree, RemcoMäkitie, Antti A.Franchi, AlessandroHellquist, HenrikSaba, Nabil F.Stenman, GöranTakes, Robert P.Valero, CristinaZidar, NinaFerlito, Alfio2023-02-13T10:46:42Z2023-01-282023-02-10T14:28:39Z2023-01-28T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/19065engCancers 15 (3): 802 (2023)10.3390/cancers150308022072-6694info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:31:27Zoai:sapientia.ualg.pt:10400.1/19065Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:08:43.654495Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
title Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
spellingShingle Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
Rodrigo, Juan P.
Oropharyngeal squamous cell carcinoma
Meta-analysis
Neutrophil-to-lymphocyte ratio
Prognosis
title_short Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
title_full Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
title_fullStr Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
title_full_unstemmed Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
title_sort Neutrophil to lymphocyte ratio in oropharyngeal squamous cell Carcinoma: A systematic review and meta-analysis
author Rodrigo, Juan P.
author_facet Rodrigo, Juan P.
Sánchez-Canteli, Mario
Triantafyllou, Asterios
de Bree, Remco
Mäkitie, Antti A.
Franchi, Alessandro
Hellquist, Henrik
Saba, Nabil F.
Stenman, Göran
Takes, Robert P.
Valero, Cristina
Zidar, Nina
Ferlito, Alfio
author_role author
author2 Sánchez-Canteli, Mario
Triantafyllou, Asterios
de Bree, Remco
Mäkitie, Antti A.
Franchi, Alessandro
Hellquist, Henrik
Saba, Nabil F.
Stenman, Göran
Takes, Robert P.
Valero, Cristina
Zidar, Nina
Ferlito, Alfio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Sapientia
dc.contributor.author.fl_str_mv Rodrigo, Juan P.
Sánchez-Canteli, Mario
Triantafyllou, Asterios
de Bree, Remco
Mäkitie, Antti A.
Franchi, Alessandro
Hellquist, Henrik
Saba, Nabil F.
Stenman, Göran
Takes, Robert P.
Valero, Cristina
Zidar, Nina
Ferlito, Alfio
dc.subject.por.fl_str_mv Oropharyngeal squamous cell carcinoma
Meta-analysis
Neutrophil-to-lymphocyte ratio
Prognosis
topic Oropharyngeal squamous cell carcinoma
Meta-analysis
Neutrophil-to-lymphocyte ratio
Prognosis
description Neutrophil-to-lymphocyte ratio (NLR) has been associated with survival in various cancers, including head and neck cancer. However, there is limited information on its role in oropharyngeal squamous cell carcinomas (OPSCC) according to HPV status. This prompted the present metaanalysis. Studies were selected when the prognostic value of NLR prior to treatment was evaluated in OPSCC patients, the cutoff value of NLR was available, and the prognostic value of NLR was evaluated by time-to-event survival analysis. A total of 14 out of 492 articles, including 7647 patients, were analyzed. The results showed a worse prognosis for the patients with a high NLR: The combined hazard ratios (HR) for overall survival (OS) in patients with an elevated NLR was 1.56 (95% confidence interval (CI) 1.21–2.02; p = 0.0006), for disease-free survival was 1.52 (95% CI 1.34–1.73; p < 0.00001), and for recurrence-free survival was 1.86 (95% CI 1.50–2.30; p < 0.00001). This worse prognosis ofhigh NLR was exclusive of HPV-positive patients: HR for OS in the HPV-positive subgroup was 4.05 (95% CI 1.90–8.62 (p = 0.0003), and in the HPV-negative subgroup 0.92 (95% CI 0.47–1.80; p = 0.82). The prognosis of NLR was not influenced by treatment: The HR for OS for patients treated with radiotherapy/chemoradiotherapy (RT/CRT) was 1.48 (95% CI 1.09–2.01; p = 0.01), and for patients treated with surgery (±RT/CRT) was 1.72 (95% CI 1.08–2.72; p = 0.02). In conclusion, an elevated NLR relates to worse outcomes in patients with HPV-positive OPSCC.
publishDate 2023
dc.date.none.fl_str_mv 2023-02-13T10:46:42Z
2023-01-28
2023-02-10T14:28:39Z
2023-01-28T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.1/19065
url http://hdl.handle.net/10400.1/19065
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Cancers 15 (3): 802 (2023)
10.3390/cancers15030802
2072-6694
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133334245212160